Transport of drugs across the hepatic sinusoidal membrane: Sinusoidal drug influx and efflux in the liver

Seminars in Liver Disease

Volumn 20, Issue 3, 2000, Pages 251-263

  Suzuki, H ^a   Sugiyama, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Multi drug resistance associated protein; Organic anion transporter; Organic anion transporting polypeptide; Organic cation transporter

Indexed keywords

7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; CARRIER PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCURONIDE; GLUTATHIONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METAL CHELATE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTING POLYPEPTIDE; PROSTAGLANDIN TRANSPORTER; STEROID; TAUROCHOLIC ACID; TEMOCAPRILAT; THYROID HORMONE; UNCLASSIFIED DRUG;

ANION TRANSPORT; CATION TRANSPORT; DRUG TRANSPORT; EFFUSION; HUMAN; LIVER SINUSOID; MOLECULAR CLONING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRANSPORT KINETICS;

EID: 0033736560     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-8408     Document Type: Review

References (119)

1. Uptake is the rate-limiting step in the overall hepatic eliminaion of pravastatin at steady-state in rats
2. Determination of the rate-limiting step in the hepatic elimination of YM796 by isolated rat hepatocytes
3. Transport of organic anions in the liver. An update on bile acid, fatty acid, monocarboxylate, anionic amino acid, cholephilic organic anion, and anionic drug transport
4. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport
5. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver
6. Molecular aspects of hepatobiliary transport
7. Hepatobiliary disposition and targeting of drugs and genes
8. Regulation of organic anion and drug transporters of the sinusoidal mambrane
9. +-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells
10. Bumetanide is not transported by the Ntcp or by the oatp: Evidence for a third organic anion transporter in rat liver cells
11. Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist
12. Chlorambuciltaurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas
13. Bile acid transport systems as pharmaceutical targets
14. Modified bile acids as carriers for peptides and drugs
15. Transporters for bile acids and organic anions
16. Identification of thyroid hormone transporters
17. Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells
18. Localization and function of the organic anion-transporting polypeptide oatp2 in rat liver
19. The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein
20. Transport of temocaprilat into rat hepatocytes: Role of organic anion transporting polypeptide
21. Oatp and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
22. A novel human hepatic organic anion transporting polypeptide (OATP2): Identification of a liver-specifid human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters
23. Uptake of the mycotoxin ochratoxin A in liver cells occur via the cloned organic anion transporting polypeptide
24. 4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter
25. 3-exchange
26. Stable inducible expression of a functional rat liver organic anion transporter protein in HeLa cells
27. Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2)
28. Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2
29. Molecular and funcional characterization of an organic anion transporting polypeptide cloned from human liver
30. Dehydroepiandrosterone sulfate (DHEAS): Identification of a carrier protein in human liver and brain
31. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1
32. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane
33. Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst- 1
34. Cloning and functional characterization of a novel rat organic anion transporter mediating basolatera1 uptake of methotrexate in the kidney
35. Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney
36. Expression cloning and characterization of a novel multispecific organic anion transporter
37. Expression cloning and characterization of ROAT1, the basolateral organic anion transporter in rat kidney
38. Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes
39. The interaction and transport of β-lactam antibiotics with the cloned rat renal organic anion transporter 1
40. Transport of ochratoxin A by renal multispecific organic anion transporter 1
41. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1
42. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney
43. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver
44. Molecular cloning and characterization of a new multispecific organic anion tansporter from rat brain
45. Identification and characterization of a prostaglandin tansporter
46. Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA (hPGT)
47. Molecular mechanisms of prostaglandin transport
48. Transient expression of oatp organic anion transporters in mammalian cells: Identification of candidate substrates
49. Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes
50. Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes
51. Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes
52. Commentary: Presence of a diffusional barrier on metabolite kinteics: Enalaprilat as a generated versus preformed metabolite
53. Transfer of enalaprilat across rat liver cell membranes is barrier limited
54. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver
55. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics
56. Pravastatin, an HMG CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2
57. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on steroid synthesis in various human cell types
58. Uptake of benzylpenicillin, cefpiramide and cefazolin by freshly prepared rat hepatocytes: Evidence for a carrier-mediated transport system
59. Carrier-mediated hepatic uptake of quinolone antibiotics in the rat
60. Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent
61. Pharmacokinetic study of the hepatobiliary transport of indomethacin
62. Acinar factors in drug processing: Protein binding, futile cycling and cosubstrate
63. Membrane transport in hepatic clearance in drugs. II. Zonal distribution patterns of concentration-dependent transport and elimination processes
64. +-independent organic anion transoprting polypeptide (oatp) in rat liver and kidney
65. Uptake of galactose, ouabain and taurocholate into centrilobular and periportal enriched hepatocyte subpopulations
66. +/taurocholate cotransporting polypeptide in rat liver
67. Lack of zonal uptake of estone sulfate in enriched periportal and perivenous isolated rat hepatocytes
68. Uptake and glutathione conjugation of ethacrynic acid and efflux of the glutathione adduct by periportal and perivenous rat hepatocytes
69. Comparison of the disposition of hepatically-generated morphine-3-glucuronide and morphine-6-glucuronide in isolated perfused liver from the guinea pig
70. Kinetic analysis of hepatobiliary transport of conjugated metabolites in the perfused liver of mutant rats (EHBR) with hereditary conjugated hyperbilirubinemia
71. Carrier-mediated active transport of the glucuronide and sulfate of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) into rat liver: Quantitative comparison of permeability in isolated hepatocytes, perfused liver and liver in vivo
72. Carrier-mediated uptake and excretion of bromosulfophthalein-glutathione in perfused rat liver: A multiple indicator dilution study
73. Hepatic uptake of hippurate: A multiple-indicator dilution, perfused rat liver study
74. cDNA cloning of MCT2, a second monocarboxylate transporter expressed in different cells than MCT1
75. Excretion of the organic anion harmol sulfate from liver into blood
76. Uptake of sulfate conjugates by isolated rat hepatocytes
77. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats
78. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3)
79. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane
80. MRP3, an organic anion transporter able to transport anti-cancer drugs
81. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2
82. Conjugated export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance
83. Characterization of the transport properties of cloned rat multidrug resistance associated protein 3 (MRP3)
84. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (MRP3)
85. Carrier-mediated transport of ouabain in isolated hepatocytes
86. A multispecific uptake system for taurocholate, cardiac glycosidesw and cationic drugs in the liver
87. The stereoisimers qunine and quinidine exhibit a marked stereoselectivity in the inhibition of hepatobiliary transport of cardiac glycosides
88. Stereoselective inhibition by the diastereomers quinidine and quinine of uptake of cardiac glycosides into isolated rat hepatocytes
89. Polyspecific drug and steroid clearance by an organic anion transporter of mamalian liver
90. Multispecific amphipathic substrate transport by an organic anion transporter of human liver
91. Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations
92. Organic cation transporters in intestine, kidney, liver, and brain
93. Molecular pharmacology of organic cation tansporters in kidney
94. Role of organic cation tranpsorters in drug absorption and elimination
95. Catecholamine transport by the organic cation transporter type 1 (OCT1)
96. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa)
97. Cloning and characterization of two human polyspecific organic cation transporters
98. Cloning and functional expression of a human liver organic cation transporter
99. Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: Contribution of type I system
100. Selective substrates for non-neuronal monoamine transporters
101. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations
102. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter
103. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2
104. +-dependent carnitine transport by organic cation transoprter (OCTN2): Its pharmacological and toxicological relevance
105. Mutations in novel organic cation transporter (OCTN2), an organic cation/carnitine transporter, with differential effects on the organic cation transport function and the carnitine transport function
106. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter
107. Hepatocellular uptake of cyclosomatostatins: Evidence for a carrier system related to the multi-specific bile acid transporter
108. Hepatic uptake of octreotide, a long acting somatostain analogue, via a bile acid transport system
109. Hepatocellular uptake of peptides. II. Interaction between hydrophilic linear renin-inhibiting peptides and transport systes for endogenous substrates in liver cells
110. New substrates of multispecific bile acid transporter in liver cells: Interference of some linear renin inhibiting peptides with transport protein(s) for bile acids
111. Hepatocellular uptake of peptides by bile acid transporters: Relationship of carrier mediated transport of linear peptides with renin inhibiting activity of multispecific bile acid carriers
112. Hepatocellular uptake of peptides I. Carrier-mediated uptake of hydrophilic linear peptides with renin inhibitory activity into isolated rat liver cells
113. Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction
114. Processing of cholecystokinin by isolated liver cells
115. Hepatobiliary elimination of certain peptide-mimicing drugs: Linear hydrophobic and hydrophilic renin-inhibitors and hydrophobic cyclopeptides
116. Carrier mediated active transport of BQ-123, a peptide endothelin antagonist, into rat hepatocytes
117. Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123
118. Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats
119. Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats